Cardiovascular Safety and Efficacy of the PCSK9 Inhibitor Evolocumab in Patients With and Without Diabetes and the Effect of Evolocumab on Glycaemia and Risk of New-Onset Diabetes: A Prespecified Analysis of the FOURIER Randomised Controlled Trial
Sabatine MS, Leiter LA, Wiviott SD, et al.
Lancet Diabetes Endocrinol. Pub. online September 15, 2017
Leggi


